- Secures high-quality investment structure: 72% foreign capital, RCPS, and 1-year lock-up period.
- Passes global validation, leading to a revaluation of enterprise value.

ROKIT Healthcare (KOSDAQ 376900), a specialist in AI-driven hyper-personalized organ regeneration platforms, has secured a large-scale investment totaling 62.5 billion KRW from prominent global private equity funds and asset managers. This move provides the company with significant capital to accelerate its global market expansion.

This investment is drawing intense market attention, as it goes beyond simple fundraising. It signifies that global institutional investors have placed full confidence in Rokit Healthcare’s long-term growth roadmap.

■ 45 Billion KRW in Global Capital: Global Funds Take the Lead

A key highlight of this investment is the overwhelming proportion of foreign capital. Approximately 72% of the total investment (45 billion KRW) consists of overseas capital.

Detailed participants include highly influential global institutions such as:

- Weiss Asset Management (30 billion KRW)
- Oasis Management (7 billion KRW)
- Pacific Alliance Group (PAG) (5 billion KRW)
- LMR Partners (3 billion KRW)

On the domestic front, leading institutions including NH Investment & Securities, Assem, Anda, GVA, and Milestone Asset Management supported the round with an additional 17.5 billion KRW.

An investment banking (IB) industry insider noted, "A structure where top-tier global institutions move first, followed by domestic institutions, is a classic case of 'Global Validation.' It serves as a powerful signal that the company’s technology and business model are competitive on the world stage."

■ ‘RCPS + 1-Year Lock-up’: Mitigating Short-term Supply Pressure, Securing Long-term Momentum

The investment structure is designed to be highly favorable for both the issuer and existing shareholders. The funding was conducted via Redeemable Convertible Preferred Shares (RCPS) with a one-year lock-up condition, which limits the burden of short-term floating supply. By blocking potential sell-offs for a year, the company has effectively mitigated concerns regarding a short-term 'overhang' (large pending supply), a common issue during rights offerings or Convertible Bond (CB) issuances.

■ Betting on a Long-term Growth Story: Anticipating a ‘Quantum Jump’ in Market Cap

Experts predict this investment will create a three-stage virtuous cycle for Rokit Healthcare’s stock price: 'short-term positive news, medium-term strength, and long-term revaluation.' Given that the investment horizon is long and the funds are earmarked for R&D and clinical trials of major pipelines, a significant revaluation of the company's market capitalization is expected once revenue growth becomes tangible.

A representative from Rokit Healthcare stated, "The influx of 62.5 billion KRW in 'smart money' will serve as a turning point for Rokit Healthcare to emerge as a global leader in the bio and regenerative medicine sectors. The entry price of these global institutions is expected to act as a strong support level for the stock price, likely driving a long-term upward trajectory."